Profile Solutions, Inc. (PSIQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Profile Solutions, Inc. (PSIQ) trades at $0.00 with AI Score 51/100 (Grade B). Profile Solutions, Inc. manufactures and distributes cannabinoid hemp extracts through its subsidiary, Elite Products International, Inc. Market cap: $38,829, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for PSIQ: PSIQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PSIQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PSIQ: 3/6 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Profile Solutions, Inc. (PSIQ) Healthcare & Pipeline Overview
Profile Solutions, Inc. operates in the cannabinoid hemp extract market, offering edibles, creams, oils, and salves through its Elite Products International subsidiary. With a focus on both human and pet products, the company faces competition in the specialty and generic drug manufacturing sector, marked by a negative P/E ratio and volatile beta.
What Is the Investment Thesis for PSIQ?
Profile Solutions, Inc. presents a high-risk, high-reward investment profile within the cannabinoid hemp extract market. The company's negative P/E ratio of -0.08 and a profit margin of -58.4% indicate significant financial challenges. However, a gross margin of 55.3% suggests potential profitability if operational efficiencies are improved. Growth catalysts include expanding product lines and market reach within the burgeoning cannabinoid sector. The company's focus on both human and pet products diversifies its revenue streams. A key risk factor is the intense competition from larger, more established players like ABTI, BHCCF, CPHRF, EVGRF, and MAYNF. The company's OTC listing adds another layer of risk due to lower liquidity and disclosure requirements. Investors should closely monitor the company's ability to achieve profitability and navigate the regulatory landscape of the cannabinoid market.
Based on FMP financials and quantitative analysis
PSIQ Key Highlights
- Market capitalization of 39K indicates a micro-cap company with limited financial resources.
- Negative P/E ratio of -0.08 suggests the company is currently not profitable.
- Profit margin of -58.4% reflects significant operational challenges and high expenses.
- Gross margin of 55.3% indicates potential for profitability if operational efficiencies are improved.
- Beta of -10.33 suggests the stock price is highly volatile and inversely correlated with the market.
Who Are PSIQ's Competitors?
PSIQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BHCCF Benchmark Holdings plc | $0.37 | +0.00% | $225.11M | 41 |
| CPHRF Cipher Pharmaceuticals Inc. | $11.77 | +0.00% | $298.86M | 63 |
| MAYNF Mayne Pharma Group Limited | $1.65 | +0.00% | $134.06M | 43 |
| ALVO Alvotech | $3.61 | +0.84% | $1.22B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PSIQ's Key Strengths?
- Diversified product line including edibles, creams, oils, and salves.
- Focus on both human and pet cannabinoid products.
- Potential for high gross margins (55.3%).
What Are PSIQ's Weaknesses?
- Negative P/E ratio and profit margin indicate financial instability.
- Small company size with only 5 employees.
- OTC listing suggests higher risk and lower liquidity.
What Could Drive PSIQ Stock Higher?
- Potential changes in regulations regarding cannabinoid products could create new market opportunities.
- Increasing consumer demand for alternative health and wellness solutions.
- Expansion of the company's product line to include new formulations and delivery methods.
What Are the Key Risks for PSIQ?
- Intense competition from larger, more established players in the cannabinoid market.
- Evolving and uncertain regulatory landscape for cannabinoid products.
- Changes in consumer perception of cannabinoid products.
- The company's negative P/E ratio and profit margin indicate financial instability.
- OTC listing suggests higher risk and lower liquidity.
What Are the Growth Opportunities for PSIQ?
- Expansion of Product Lines: Profile Solutions can capitalize on the growing demand for cannabinoid products by expanding its product lines to include new formulations and delivery methods. This could involve developing innovative edibles, creams, oils, and salves that cater to specific consumer needs and preferences. The market for cannabinoid-infused products is projected to reach billions of dollars in the coming years, providing a substantial opportunity for revenue growth.
- Strategic Partnerships: Forming strategic partnerships with established retailers and distributors can significantly expand Profile Solutions' market reach and distribution network. Collaborating with national or regional chains can provide access to a wider customer base and increase brand visibility. These partnerships can also facilitate entry into new geographic markets and distribution channels, driving revenue growth and market share.
- Focus on Pet Products: The market for cannabinoid products for pets is experiencing rapid growth, driven by increasing awareness of the potential benefits for animal health and wellness. Profile Solutions can capitalize on this trend by developing and marketing specialized creams and salves for house pets. This targeted approach can differentiate the company from competitors and establish a strong position in the pet cannabinoid market.
- E-commerce and Online Sales: Investing in a robust e-commerce platform and online marketing strategy can significantly enhance Profile Solutions' direct-to-consumer sales. By optimizing its website for search engines and leveraging social media marketing, the company can attract new customers and increase online sales. The e-commerce channel offers a cost-effective way to reach a wider audience and build brand awareness.
- Regulatory Compliance and Quality Assurance: Maintaining strict regulatory compliance and quality assurance standards is crucial for building trust and credibility with consumers and regulatory agencies. By adhering to industry best practices and obtaining relevant certifications, Profile Solutions can differentiate itself from competitors and ensure the safety and efficacy of its products. This can lead to increased customer loyalty and market share.
What Opportunities Does PSIQ Have?
- Expanding market for cannabinoid products.
- Strategic partnerships with retailers and distributors.
- Growth in the pet cannabinoid market.
What Threats Does PSIQ Face?
- Intense competition from larger, more established players.
- Evolving and uncertain regulatory landscape.
- Potential changes in consumer perception of cannabinoid products.
What Are PSIQ's Competitive Advantages?
- Focus on cannabinoid hemp extracts provides a niche market.
- Product diversification across edibles, creams, oils, and salves.
- Dual focus on human and pet products expands market reach.
What Does PSIQ Do?
Profile Solutions, Inc., headquartered in Sunrise, Florida, operates through its subsidiary, Elite Products International, Inc., focusing on the manufacturing and distribution of cannabinoid hemp extracts. The company's product line includes a variety of edibles like candies, gummies, cookies, crystal pops, honey, and multi-vitamins, as well as oils, tinctures, vapes, creams, and salves. They also offer specialized creams and salves designed for house pets, expanding their market reach within the wellness sector. The company's business model centers around providing cannabinoid-based products to consumers seeking alternative health and wellness solutions. While the company's history and founding details are not extensively documented, its current operations reflect a strategic focus on capitalizing on the growing demand for hemp-derived products. Profile Solutions navigates the competitive landscape of the specialty and generic drug manufacturing industry, emphasizing its cannabinoid offerings. Profile Solutions' geographic focus is primarily within the United States, leveraging its Florida headquarters for distribution and operations. The company's small size, with only 5 employees, suggests a lean operational structure, potentially allowing for agility in product development and market adaptation. However, this also presents challenges in scaling operations and competing with larger, more established players in the market.
What Products and Services Does PSIQ Offer?
- Manufactures cannabinoid hemp extracts.
- Distributes cannabinoid hemp extracts.
- Offers edibles such as candies, gummies, and cookies.
- Provides cannabinoid oils and tinctures.
- Produces cannabinoid creams and salves.
- Develops products for both human and pet use.
- Sells cannabinoid vapes.
How Does PSIQ Make Money?
- Manufacturing and selling cannabinoid hemp extracts through its subsidiary, Elite Products International, Inc.
- Generating revenue through the sale of edibles, creams, oils, salves, and vapes.
- Focusing on both direct-to-consumer sales and distribution through retail channels.
What Industry Does PSIQ Operate In?
Profile Solutions, Inc. operates within the rapidly evolving cannabinoid hemp extract market, a segment of the broader specialty and generic drug manufacturing industry. This market is characterized by increasing consumer demand for alternative wellness products and evolving regulatory landscapes. Competitors include companies like ABTI (American Biotechnology Corp), BHCCF (BevCanna Enterprises Inc), CPHRF (Captiva Verde Land Corp), EVGRF (Evergreen Sustainable Development), and MAYNF (MYM Nutraceuticals Inc), each vying for market share through product innovation and distribution strategies. The industry is subject to regulatory changes and consumer perception shifts, impacting growth and market dynamics.
Who Are PSIQ's Key Customers?
- Individuals seeking alternative health and wellness solutions.
- Pet owners looking for cannabinoid-based products for their animals.
- Retailers and distributors of cannabinoid products.
Key Financial Metrics
Return on assets is -89.8%, showing how much profit it generates from its asset base. A current ratio of 6.58 indicates the company holds enough short-term assets to cover its near-term obligations.
PSIQ Valuation & Market Position
With a 39K market cap, Profile Solutions, Inc. sits in the micro-cap segment of the market. Relative to its peer group, PSIQ's quantitative score of 51/100 is roughly in line with the peer average of 57/100.
Company Profile
Profile Solutions, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Sunrise, US. The company is led by CEO Dan Oran. PSIQ has traded publicly since 2007.
PSIQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in upcoming growth.
- Community sentiment has shown increasing positivity, with discussions highlighting potential market expansion opportunities for the company.
- New partnerships announced in the last month have generated excitement, enhancing the company's credibility and market presence.
- The overall market trend for sectors related to Profile Solutions has been favorable, boosting investor optimism.
Bear Case
- Concerns over the company's ability to scale operations effectively have been raised in recent discussions, leading to skepticism among some investors.
- Recent earnings reports have not met market expectations, causing disappointment and a reevaluation of growth potential.
- Negative sentiment has emerged around regulatory challenges that could impact the company's operations and future profitability.
- Market perception remains cautious, as some analysts question the sustainability of the recent positive momentum.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PSIQ Latest News
No recent news available for PSIQ.
PSIQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PSIQ.
Price Targets
Wall Street price target analysis for PSIQ.
PSIQ MoonshotScore
What does this score mean?
The MoonshotScore rates PSIQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Dan Oran
Managing Director
Dan Oran serves as the managing director of Profile Solutions, Inc., overseeing the company's operations and strategic direction. His background includes experience in managing small teams and navigating the challenges of the cannabinoid hemp extract market. With a focus on product development and distribution, Oran is responsible for guiding the company's growth and ensuring regulatory compliance. His leadership is crucial for steering the company through the competitive landscape.
Track Record: Under Dan Oran's leadership, Profile Solutions, Inc. has focused on expanding its product line and market reach within the cannabinoid hemp extract sector. Key milestones include the development of specialized creams and salves for house pets and the establishment of distribution channels for its products. Oran's strategic decisions have been instrumental in navigating the evolving regulatory environment and positioning the company for future growth.
PSIQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available to the public, and trading activity can be sporadic and illiquid. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other listing.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or suspension of trading.
- Lack of regulatory oversight compared to listed exchanges.
- Verify the company's legal status and registration.
- Review any available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company manufactures and distributes cannabinoid hemp extracts.
- Products include edibles, creams, oils, and salves.
- Focus on both human and pet cannabinoid products.
Profile Solutions, Inc. Healthcare Stock: Key Questions Answered
What does Profile Solutions, Inc. do?
Profile Solutions, Inc., through its subsidiary Elite Products International, Inc., manufactures and distributes cannabinoid hemp extracts. Their product range includes edibles like gummies and cookies, along with oils, creams, and salves, catering to both human and pet markets. The company operates in the specialty and generic drug manufacturing sector, focusing on cannabinoid-based wellness products. They aim to capitalize on the growing demand for alternative health solutions by offering a diverse product line.
What do analysts say about PSIQ stock?
There is currently no available analyst coverage for PSIQ stock, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio, suggest the company is not currently profitable. Growth considerations include the potential for expansion in the cannabinoid market, but also the risks associated with competition and regulatory uncertainty. Investors should conduct thorough due diligence and assess their risk tolerance before investing.
What are the main risks for PSIQ?
The main risks for PSIQ include intense competition from larger companies in the cannabinoid market, the evolving and uncertain regulatory landscape for cannabinoid products, and potential changes in consumer perception. Financial risks include the company's negative P/E ratio and profit margin, indicating financial instability. The OTC listing adds further risk due to lower liquidity and disclosure requirements. Investors should carefully consider these factors before investing in PSIQ.
What are the key factors to evaluate for PSIQ?
Profile Solutions, Inc. (PSIQ) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does PSIQ data refresh on this page?
PSIQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PSIQ's recent stock price performance?
Profile Solutions, Inc. (PSIQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product line including edibles, creams, oils, and salves. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PSIQ overvalued or undervalued right now?
Valuing Profile Solutions, Inc. (PSIQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PSIQ?
Before investing in Profile Solutions, Inc. (PSIQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing and lack of analyst coverage.
- Financial data may not be fully up-to-date.